Literature DB >> 28820067

Comprehensive Review on Ebola (EBOV) Virus: Future Prospects.

Sajad Khan1, Abdur Rauf2, Ahsan Khan3, Muhammad Rizwan4, Seema Patel5, Haroon Khan6, Adel M Mahasneh7, Mohammad S Mubarak8.   

Abstract

Ebola virus (EBOV) was discovered for the first time in 1976. It belongs to the family Filoviridae, which causes hemorrhagic fever that could lead to death in a few days. West Africa faced a major outbreak where symptoms appeared in the form of chills, myalgia, fever, diarrhea, and vomiting, and the disease finally reached a severe state as a result of hemorrhagic complications and failure of multiple organs. EBOV spreads by contact with body fluids of an infected person such as blood, saliva, urine, and seminal fluid, and also spreads by a contact with contaminated surfaces. Viral infection depends on the virus and host defenses. When the virus invades the body, the immune system becomes activated in an attempt to neutralize it. However, if this fails, EBOV viral infection spreads and leads to impaired innate and adaptive immune responses and uncontrollable viral replication. Consequently, the symptomatic patient is isolated and various medicinal regimens such as BCX-4430n TKM- EBOV are used, to cure EBOV, though, a specific treatment is not available. Accordingly, the aim of the present review is to survey and summarize the recent literature pertaining to the outbreak of EBOV, systematic infection of the human body, along with transmission and treatment. In addition, the review also aims to identify areas that need more research and development in combatting this dangerous virus. In the meantime, it should be noted that there is no fully FDA approved drug to treat infections by this virus. Therefore, there is a pressing need to focus on drug discovery along with public awareness to effectively manage any outbreaks in the future. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  EBOV; Filoviridae; fever; infection; replication; transmission.

Mesh:

Substances:

Year:  2018        PMID: 28820067     DOI: 10.2174/1871526517666170817100828

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  2 in total

1.  Molecular mechanism of mureidomycin biosynthesis activated by introduction of an exogenous regulatory gene ssaA into Streptomyces roseosporus.

Authors:  Ning Liu; Hanye Guan; Guoqing Niu; Lingjuan Jiang; Yue Li; Jihui Zhang; Jine Li; Huarong Tan
Journal:  Sci China Life Sci       Date:  2021-02-09       Impact factor: 6.038

2.  The m6A methylome of SARS-CoV-2 in host cells.

Authors:  Jun'e Liu; Yan-Peng Xu; Kai Li; Qing Ye; Hang-Yu Zhou; Hanxiao Sun; Xiaoyu Li; Liu Yu; Yong-Qiang Deng; Rui-Ting Li; Meng-Li Cheng; Bo He; Jia Zhou; Xiao-Feng Li; Aiping Wu; Chengqi Yi; Cheng-Feng Qin
Journal:  Cell Res       Date:  2021-01-28       Impact factor: 46.297

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.